We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Ultraspeed Resolution Reveals that Ubiquitins Bind Sequentially

By LabMedica International staff writers
Posted on 15 Dec 2009
An innovative reaction quenching protocol with millisecond resolution has revealed that cells attach ubiquitin chains to proteins marked for destruction link by link rather than all at once. More...


The addition of a chain of four or more ubiquitin molecules to a target protein marks that protein for destruction by protein-degrading complexes in the cell. Heretofore, it was not known whether these molecules were added to the target protein sequentially or as a pre-formed chain.

In the current study, investigators at California Institute of Technology (Pasadena, USA) developed new methodology to study the action of ubiquitin ligase, the enzyme complex that attaches ubiquitin to the target protein at short time intervals that had not previously been possible. For this purpose, they adapted an instrument called a "quench-flow" machine, a machine that allows for extreme precision in the stopping, or "quenching," of a reaction. This instrument allowed them to follow changes in structure at intervals as short as 10 milliseconds in both yeast and human proteins.

"We devised methods to take snapshots of ubiquitin ligase reactions at a rate of up to 100 "pictures" every second," said senior author Dr. Raymond Deshaies, professor of biology at the California Institute of Technology. "This enables us to see things that would normally evade detection. Prior methods did not have sufficient time resolution to see what was going on. It is as if you gave an ice-cream cone to a kid and took pictures every minute. You would see the ice cream disappear from the first photo to the next, but since the pictures are too far apart in time, you would have no idea whether the child ate the ice cream one bite at a time, or swallowed the entire scoop in one gulp."

Results published in the December 3, 2009, issue of the journal Nature revealed that the three ubiquitin ligase enzymes, E1, E2, and E3 work as a team to build polyubiquitin chains on substrates by sequential transfers of single ubiquitins.

"The new method revealed the biological equivalent of small, single bites of ice cream," said Dr. Deshaies. "Using our approach we could see that our ubiquitin ligase builds ubiquitin chains one ubiquitin at a time. Gaining these kinds of insights into the ubiquitin system is important because ubiquitin ligases play a critical role in a number of human diseases, including cancer, due to their role in the regulation of the cell cycle."

Related Links:
California Institute of Technology



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.